PA-BOOMI
16.5.2023 16:01:30 CEST | Business Wire | Press release
BoomiTM, the intelligent connectivity and automation leader, today announced Boomi AI – a first-of-its-kind, simplified user experience that harnesses generative AI to connect and integrate applications, data, processes, people, and things across organizations – creating business outcomes faster than ever before.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005335/en/
Boomi Changes the Integration and Automation Game With Boomi AI (Graphic: Business Wire)
“The introduction of Boomi AI marks yet another milestone in our long history of pioneering innovation in the integration industry,” said Ed Macosky, Chief Product Officer at Boomi. “We pioneered the first low-code, cloud-native integration platform as a service (iPaaS) to disrupt the middleware market 20+ years ago. Then, over a decade ago, Boomi pioneered AI-assisted development with the launch of Boomi Suggest, which further disrupted the market. Now, we are taking our intelligent integration and automation platform to the next level by making it AI-first – enabling AI to responsibly build and complete integrations, and transform automation for our customers.”
In today’s constantly changing market, organizations are making substantial investments to modernize their digital operations. According to IDC, global spending on AI will increase by 26.9% in this next year alone. However, disconnected ecosystems make it difficult for IT teams to focus on strategic initiatives. Fragmented tools, applications, and data can cause confusion and coordination issues, as teams lack a centralized platform for integration, API management, orchestration, and automation, resulting in time spent on maintenance, not innovation.
Boomi’s AI engine is fueled by the company’s approximately 20,000 customers – the largest customer base among integration platform vendors. Boomi AI leverages anonymized metadata, patterns, and best practices from the 200 million integrations made with the Boomi platform to train the AI models to create high-quality integrations across various business processes and applications, such as data management, customer experience optimization, or supply chain processes.
“Boomi’s extensive knowledge base makes our AI engine far more advanced than the AI-assisted development tools available today. It also benefits users by continuously testing patterns to ensure optimal integration design and root out risks and errors early, enabling customers to achieve tremendous gains in efficiency, operational improvements, and other desirable business outcomes,” added Macosky.
With Boomi AI, organizations can:
Design Connections: Boomi AI can design integration processes, application programming interfaces, and master data models with built-in best practices from millions of successful use cases, through a quick command, like, “Connect my CRM and invoice systems.”
Optimize Operations: With Boomi AI’s actionable intelligent insights, users can solve problems proactively, facilitate predictive maintenance, automate updates, and allocate optimal resources to enable software to efficiently self-manage itself. These insights, like “A data attribute in Salesforce has changed. Would you like to apply it across your systems?” make previously menial tasks quick and easy.
Orchestrate Experiences: Boomi AI can interpret intent behind desired business outcomes to orchestrate processes across applications. It enhances decision-making, simplifies tasks, and improves engagement while providing audit history and prompts to confirm intent so that decisions and outcomes are always explainable, creating even greater synergies between IT and the business. With a simple prompt like “Automate invoice processing,” IT teams and business leaders can focus on what matters most.
Enable Responsible AI Development: Boomi’s AI algorithms are trained to avoid biases and unfairness with established ethical guidelines for the development and use of AI within the Boomi platform. These guidelines confirm that Boomi’s AI technology is used in a transparent and accountable manner, and that it does not violate any ethical principles or laws. Additionally, Boomi has achieved U.S. Federal Risk and Authorization Management Program (FedRAMP) Authorization Moderate, a government-wide program that provides a standardized approach to security assessment. Boomi AI does not store any customer-specific information of any kind.
“In today's fast-paced market, organizations need more powerful tools that enable them to outperform, and AI presents a potent new avenue to do this,” says Dion Hinchcliffe, VP and Principal Analyst of Constellation Research. “By embracing an important new AI-first approach, organizations can unlock new levels of efficiency, innovation, and competitive advantage, to immediately capture opportunity as well as ensure their business remains future-ready.”
As the pioneer of cloud-native integration platform as a service (iPaaS), Boomi celebrates a growing community of more than 100,000 members, and one of the largest arrays of global systems integrators (GSIs) in the iPaaS space. The company boasts a worldwide network of partners, including Accenture, Deloitte, SAP, and Snowflake; and works with the largest hyperscaler cloud service providers, including Amazon Web Services, Google, and Microsoft, among others.
Included on the Deloitte Technology Fast 500™ and Inc. 5000 lists as one of America’s fastest growing and most innovative technology companies, Boomi was recently named to Nucleus Research's list of “Hot Companies to Watch in 2023.” The company has also won numerous awards, including three International Stevie® Awards, for Company of the Year (two years in a row) and Product Innovation; the Gold Globee® Award in the Platform as a Service (PaaS) category; the Merit Award for Technology in the Cloud Services category; the Stratus Award as a Global Leader in Cloud Computing 2022; and received the prestigious 5-star rating in the CRN Partner Program Guide for two consecutive years.
Join the Boomi AI waitlist at boomi.ai.
Additional Resources
- Read more about accelerating outcomes with Boomi AI
- Learn more about the Boomi platform
- Explore the Boomiverse Community
- Follow Boomi on Twitter, LinkedIn, Facebook, and YouTube
About Boomi
Boomi aims to make the world a better place by connecting everyone to everything, anywhere. The pioneer of cloud-based integration platform as a service (iPaaS), and now a category-leading, global software as a service (SaaS) company, Boomi touts the largest customer base among integration platform vendors and a worldwide network of approximately 800 partners – including Accenture, Capgemini, Deloitte, SAP, and Snowflake. Global organizations turn to Boomi’s award-winning platform to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com.
© 2023 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005335/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
